Palatin Technologies (PTN) Research & Development (2010 - 2026)
Palatin Technologies' (PTN) quarterly Research & Development came in at $3.5 million in Q1 2026, down 6.34% YoY from $3.8 million in Q1 2025, and down 18.58% on a QoQ basis from $4.3 million in Q4 2025.
Palatin Technologies (PTN) Research & Development (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 16 years of Research & Development data on file, last reported at $3.5 million in Q1 2026.
- Quarterly Research & Development fell 6.34% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (down 29.93% YoY) and the FY2025 annual result came in at $14.9 million, down 33.49% from the prior year.
- Research & Development slipped to $3.5 million in Q1 2026, from $4.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $7.4 million in Q2 2022 to a low of $2.0 million in Q2 2025.
- A 5-year average of $4.9 million and a median of $4.8 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 113.57% — and 2025, when it sank 57.83%.
- Tracing PTN's Research & Development over 5 years: stood at $4.4 million in 2022, then climbed by 27.17% to $5.6 million in 2023, then slumped by 38.25% to $3.4 million in 2024, then rose by 25.96% to $4.3 million in 2025, then decreased by 18.58% to $3.5 million in 2026.
- The last three Research & Development figures came in at $3.5 million (Q1 2026), $4.3 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Palatin Technologies | 40.86 Mn | 40.86 Mn | - | 3.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.52 Mn |
| Dec 31, 2025 | 4.32 Mn |
| Sep 30, 2025 | 2.53 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 3.76 Mn |
| Dec 31, 2024 | 3.43 Mn |
| Sep 30, 2024 | 5.74 Mn |
| Jun 30, 2024 | 4.67 Mn |
| Mar 31, 2024 | 7.16 Mn |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 5.01 Mn |
| Jun 30, 2023 | 7.41 Mn |
| Mar 31, 2023 | 4.83 Mn |
| Dec 31, 2022 | 4.37 Mn |
| Sep 30, 2022 | 6.03 Mn |
| Jun 30, 2022 | 7.44 Mn |
| Mar 31, 2022 | 4.98 Mn |
| Dec 31, 2021 | 5.43 Mn |
| Sep 30, 2021 | 3.48 Mn |
| Jun 30, 2021 | 3.48 Mn |